MedTrace Logo

A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer

NCT01246960 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 168

Last updated 2014-10-08

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether ramucirumab when used in conjunction with chemotherapy treatment can help participants with stomach, esophagus, and gastroesophageal cancer.

Conditions

  • Stomach Cancer
  • Esophageal Cancer

Interventions

BIOLOGICAL

Ramucirumab

Administered intravenously

DRUG

Placebo

Administered intravenously

DRUG

Oxaliplatin

Administered intravenously

DRUG

Leucovorin

Administered intravenously

DRUG

5-Fluorouracil

Administered intravenously

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-09-30
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01246960 on ClinicalTrials.gov